Trexquant Investment LP Has $11.25 Million Holdings in Eli Lilly and Company $LLY

Key Points

• Trexquant Investment LP increased its stake in Eli Lilly and Company by 208.1% in the first quarter, now holding 13,619 shares valued at approximately $11.25 million.
• Eli Lilly recently reported a quarterly EPS of $6.31, surpassing analyst estimates significantly, with a revenue of $15.56 billion and a net margin of 25.91%.
• The company announced a quarterly dividend of $1.50 per share, translating to an annualized dividend of $6.00 with a yield of 0.8%, set to be paid on September 10th.

Trexquant Investment LP lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 208.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,619 shares of the company's stock after acquiring an additional 9,198 shares during the period. Trexquant Investment LP's holdings in Eli Lilly and Company were worth $11,248,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Gerber Kawasaki Wealth & Investment Management grew its stake in shares of Eli Lilly and Company by 18.8% in the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 7,745 shares of the company's stock valued at $6,397,000 after acquiring an additional 1,223 shares in the last quarter. Landscape Capital Management L.L.C. grew its stake in shares of Eli Lilly and Company by 1.3% in the first quarter. Landscape Capital Management L.L.C. now owns 4,984 shares of the company's stock valued at $4,116,000 after acquiring an additional 65 shares in the last quarter. Mission Creek Capital Partners Inc. grew its stake in shares of Eli Lilly and Company by 1.5% in the first quarter. Mission Creek Capital Partners Inc. now owns 1,264 shares of the company's stock valued at $1,044,000 after acquiring an additional 19 shares in the last quarter. Northstar Financial Companies Inc. grew its stake in shares of Eli Lilly and Company by 3.2% in the first quarter. Northstar Financial Companies Inc. now owns 1,116 shares of the company's stock valued at $922,000 after acquiring an additional 35 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp grew its stake in shares of Eli Lilly and Company by 312.6% in the first quarter. OMERS ADMINISTRATION Corp now owns 159,567 shares of the company's stock valued at $131,788,000 after acquiring an additional 120,895 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.1%

Shares of NYSE LLY opened at $732.41 on Friday. The company has a 50 day simple moving average of $748.68 and a 200 day simple moving average of $786.10. The firm has a market cap of $693.20 billion, a PE ratio of 47.87, a price-to-earnings-growth ratio of 1.02 and a beta of 0.44. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $969.65. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Insiders Place Their Bets

In other news, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. HSBC upgraded shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their price objective for the stock from $675.00 to $700.00 in a research note on Wednesday. Guggenheim reduced their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Cantor Fitzgerald reduced their price objective on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Finally, UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.